• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
164184 165 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

6 U  [; b/ M5 o: o8 D1 G2 d! T可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
5 y: C8 j/ q& X! Y" }
2 H/ K7 p3 A7 f* ]/ e& s  N& C8 F; i4 l1 V
Sub-category:
6 J- U4 ?8 n' f6 C: Z$ T4 oMolecular Targets 6 z' v4 f- C' C3 g+ ?5 s

' f5 G% Z5 I& D& V
+ R: t+ i( U* L5 V1 t4 y* iCategory:
+ i; P. y3 h' b2 c! p8 J; v1 a* VTumor Biology
* s2 r5 q5 F8 d0 L. @* ?0 z2 [
/ ?  x' Q5 ]/ u; z5 {6 D
5 E# _1 |; I) A" ]5 G" T& {! ]0 fMeeting:5 P6 y6 C: e7 V( ?* \  b
2011 ASCO Annual Meeting
" I1 C6 C0 @6 G& M. M& y" |& c! d6 I
# m1 `+ n; Q3 ]( v! x" C1 l" _3 B9 F6 M. k0 B6 G
Session Type and Session Title:
$ x% I3 D2 l1 @- WPoster Discussion Session, Tumor Biology
- ]) [9 q! g5 h0 O" D: T9 ^+ ]( Z) {2 G

% M' T' f) e9 A. m- Z2 t& XAbstract No:' q$ O# P, c3 c1 B2 ?! s
10517
* h; b$ ]1 D& ?% U$ t) `" i: U2 \6 Z$ ?# o' B+ r, E2 C9 D
5 _; j) Y' f8 S9 ?* _) L
Citation:9 t# B$ ]/ G% U
J Clin Oncol 29: 2011 (suppl; abstr 10517)
5 a! i* o/ X' s7 g0 I! N# h- E# |. i$ m% M& Y0 i

  R  e. h2 ]: @: b6 n6 gAuthor(s):  y8 ?* |; t' g9 L% }- H7 V- U
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ; G! j. U  X! [( j1 z
  U9 H. r0 x7 O  M
, {1 v3 j' g( T3 L" _2 {
6 `0 @+ t' r0 `# J0 e0 }. \
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 p1 t7 N( c% `* y% j4 B5 s4 y
/ E9 C5 U; f. m! M0 K* mAbstract Disclosures; G% K/ k$ Z: T/ g9 U
9 k9 ?9 @1 X  a' j! z- b
Abstract:' O) h* G' m. c
: o0 e9 p2 d6 g3 [9 g; R
- e8 `- n: u' z+ f. z/ b! N* p
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
. t1 K& S, H/ B; `. L9 A8 a6 J" _! g7 R4 `8 B) u6 ]
. g  P" _" S  H: P% r
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
8 L3 I8 F, Y$ |, g2 G& R& |没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

: y: B. U% s4 ]' ^+ l. p4 K! i; d化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 * D. F9 u" o. k& t) W  R( t( e8 a
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
& m8 \; V/ t% K2 w3 c3 |ALK一个指标医院要900多 ...
" U! Y" R6 U0 F9 U8 B; n
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
0 _4 ?6 I" w6 Z+ B1 l7 N
- Z1 Y1 G  y7 ]. Q现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表